medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2011; 10 (4)


Pre operative cardio pulmonary assessment of the liver transplant candidate

Martinez-Palli G, Cárdenas A

Idioma: Ingles.
Referencias bibliográficas: 110
Paginas: 421-433
Archivo PDF: 106.44 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Cardenas A, Gines P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 2005; 1: S124-S133.

  2. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 6: 901-6.

  3. Duran FG, Piqueras B, Romero M, Carneros JA, de Diego A, Salcedo M, et al. Pulmonary complications following orthotopic liver transplant. Transpl Int 1998: S255-S259.

  4. Xia VW, Taniguchi M, Steadman RH. The changing face of patients presenting for liver transplantation. Curr Opin Organ Transplant 2008; 3: 280-4.

  5. Plotkin J S, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996; 6: 426-30.

  6. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 9: 811-5.

  7. Oufroukhi L, Kamar N, Muscari F, Lavayssiere L, Guitard J, Ribes D, et al. Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation. Transplantation 2008; 10: 1436-42.

  8. Forman LM. Metabolic syndrome in liver transplantation: the elephant in the room. Liver Transpl 2008; 9: 1245-8.

  9. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009; 1: 294-304.

  10. Dec GW, Kondo N, Farrell ML, Dienstag J, Cosimi AB, Semigran MJ. Cardiovascular complications following liver transplantation. Clin Transplant 1995; 6: 463-71.

  11. Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004; 12: 1441-53.

  12. Appleton CP, Hurst RT, Lee KS, Reuss C, Hentz JG. Longterm cardiovascular risk in the orthotopic liver transplant population. Liver Transpl 2006; 3: 352-5.

  13. Guckelberger O, Byram A, Klupp J, Neumann UP, Glanemann M, Stockmann M, et al. Coronary event rates in liver transplant recipients reflect the increased prevalence of cardiovascular risk-factors. Transpl Int 2005; 8: 967-74.

  14. Zoghbi GJ, Patel AD, Ershadi RE, Heo J, Bynon JS, Iskandrian AE. Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation. Am J Cardiol 2003; 9: 1066-71.

  15. Diedrich DA, Findlay JY, Harrison BA, Rosen CB. Influence of coronary artery disease on outcomes after liver transplantation. Transplant Proc 2008; 10: 3554-7.

  16. Carey WD, Dumot JA, Pimentel RR, Barnes DS, Hobbs RE, Henderson JM, et al. The prevalence of coronary artery disease in liver transplant candidates over age 50. Transplantation 1995; 6: 859-64.

  17. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation 1996; 8: 1180-8.

  18. Tiukinhoy-Laing SD, Rossi JS, Bayram M, De Luca L, Gafoor S, Blei A, et al. Cardiac hemodynamic and coronary angiographic characteristics of patients being evaluated for liver transplantation. Am J Cardiol 2006; 2: 178-81.

  19. Flu WJ, van Kuijk JP, Hoeks S, Bax JJ, Poldermans D. Preoperative evaluation of patients with possible coronary artery disease. Curr Cardiol Rep 2010; 4: 286-94.

  20. Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol 2010; 2: 92-137.

  21. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof EL, Fleischmann KE, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 17: 1707-32.

  22. Lester SJ, Hurst RT. Liver transplantation: do you have the heart for it? Liver Transpl 2006; 4: 520-2.

  23. Appleton CP, Hurst RT. Reducing coronary artery disease events in liver transplant patients: moving toward identifying the vulnerable patient. Liver Transpl 2008; 12: 1691-3.

  24. Plotkin JS, Johnson LB, Rustgi V, Kuo PC. Coronary artery disease and liver transplantation: the state of the art. Liver Transpl 2000; 4(Suppl. 1): S53-6.

  25. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 2: 235-40.

  26. Ehtisham J, Altieri M, Salame E, Saloux E, Ollivier I, Hamon M. Coronary artery disease in orthotopic liver transplantation: pretransplant assessment and management. Liver Transpl 2010; 5: 550-7.

  27. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation 2000; 11: 2354-6.

  28. Umphrey LG, Hurst RT, Eleid MF, Lee KS, Reuss CS, Hentz JG et al. Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. Liver Transpl 2008; 6: 886-92.

  29. Davidson CJ, Gheorghiade M, Flaherty JD, Elliot MD, Reddy SP, Wang NC, et al. Predictive value of stress myocardial perfusion imaging in liver transplant candidates. Am J Cardiol 2002; 3: 359-60.

  30. Aydinalp A, Bal U, Atar I, Ertan C, Aktas A, Yildirir A, et al. Value of stress myocardial perfusion scanning in diagnosis of severe coronary artery disease in liver transplantation candidates. Transplant Proc 2009; 9: 3757-60.

  31. Tsutsui JM, Mukherjee S, Elhendy A, Xie F, Lyden ER, O’Leary E, et al. Value of dobutamine stress myocardial contrast perfusion echocardiography in patients with advanced liver disease. Liver Transpl 2006; 4: 592-9.

  32. Oprea-Lager DE, Sorgdrager BJ, Jukema JW, Scherptong RW, Ringers J, Coenraad MJ, et al. Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates. Liver Transpl 2011; 3: 261-9.

  33. Budoff M J, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 16: 1761-91.

  34. McAvoy NC, Kochar N, McKillop G, Newby DE, Hayes PC. Prevalence of coronary artery calcification in patients undergoing assessment for orthotopic liver transplantation. Liver Transpl 2008; 12: 1725-31.

  35. Lentine KL, Hurst FP, Jindal RM, Villines TC, Kunz JS, Yuan CM, et al. Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies. Am J Kidney Dis 2010; 1: 152-67.

  36. Saner FH, Neumann T, Canbay A, Treckmann JW, Hartmann M, Goerlinger K, et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int 2011; 5: 425-32.

  37. Coss E, Watt KD, Pedersen R, Dierkhising R, Heimbach JK, Charlton MR. Predictors of cardiovascular events after liver transplantation: a role for pretransplant serum troponin levels. Liver Transpl 2011; 1: 23-31.

  38. van Werkhoven JM, Heijenbrok MW, Schuijf JD, Jukema JW, van der Wall EE, Schreur JH, et al. Combined non-invasive anatomical and functional assessment with MSCT and MRI for the detection of significant coronary artery disease in patients with an intermediate pre-test likelihood. Heart 2010; 6: 425-31.

  39. Onofrei MD, Butler KL, Fuke DC, Miller HB. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 2008; 4: 522-9.

  40. Safadi A, Homsi M, Maskoun W, Lane KA, Singh I, Sawada SG, et al. Perioperative risk predictors of cardiac outcomes in patients undergoing liver transplantation surgery. Circulation 2009; 13: 1189-94.

  41. Azarbal B, Poommipanit P, Arbit B, Hage A, Patel J, Kittleson M, et al. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. Liver Transpl 2011; 7: 809-13.

  42. Axelrod D, Koffron A, Dewolf A, Baker A, Fryer J, Baker T, et al. Safety and efficacy of combined orthotopic liver transplantation and coronary artery bypass grafting. Liver Transpl 2004; 11: 1386-90.

  43. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 2: 268-75.

  44. Zardi EM, Abbate A, Zardi DM, Dobrina A, Margiotta D, Van Tassell BW, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 7: 539-49.

  45. Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol 2010; 1: 179-90.

  46. Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009; 10: 2458-66.

  47. Cazzaniga M, Salerno F, Pagnozzi G, Dionigi E, Visentin S, Cirello I, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007; 6: 869-75.

  48. Ripoll C, Catalina MV, Yotti R, Olmedilla L, Perez-Pena J, Lo Iacono O, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation 2008; 12: 1766-72.

  49. Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS. Prediction of cardiac complications after liver transplantation. Transplantation 2009; 5: 763-70.

  50. Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol 2007; 1: 125-40.

  51. Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: is it a predictor of cardiomyopathy in cirrhosis? Clin Sci 2001; 6: 621-8.

  52. Lavi R, Lavi S, Daghini E, Lerman LO. New frontiers in the evaluation of cardiac patients for noncardiac surgery. Anesthesiology 2007; 6: 1018-28.

  53. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 1: 68-74.

  54. Hulselmans M, Vandermeulen E, Herregods MC. Risk assessment in patients with heart valve disease facing non-cardiac surgery. Act Cardiol 2009; 2: 151-5.

  55. Pollard RJ, Sidi A, Gibby GL, Lobato EB, Gabrielli A. Aortic stenosis with end-stage liver disease: prioritizing surgical and anesthetic therapies. J Clin Anesth 1998; 3: 253-61.

  56. Kertai MD, Bountioukos M, Boersma E, Bax JJ, Thomson IR, Sozzi F, et al. Aortic stenosis: an underestimated risk factor for perioperative complications in patients undergoing noncardiac surgery. Am J Med 2004; 1: 8-13.

  57. De Stephano CC, Harrison BA, Mordecai M, Crawford CC, Shine TS, Hewitt WR, et al. Anesthesia for combined cardiac surgery and liver transplant. J Cardiothorac Vasc Anesth 2010; 2: 285-92.

  58. Parker BM, Mayes JT, Henderson JM, Savage RM. Combined aortic valve replacement and orthotopic liver transplantation. J Cardiothorac Vasc Anesth 2001; 4: 474-6.

  59. Morris JJ, Hellman CL, Gawey BJ, Ramsay MA, Valek TR, Gunning TC, et al. Case 3-1995. Three patients requiring both coronary artery bypass surgery and orthotopic liver transplantation. J Cardiothorac Vasc Anesth 1995; 3: 322-32.

  60. Suhr OB. Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) patients’ symptoms and complications. Amyloid 2003: 77-83.

  61. Suhr OB, Lindqvist P, Olofsson BO, Waldenstrom A, Backman C. Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy. Amyloid 2006; 3: 154-9.

  62. Hornsten R, Wiklund U, Olofsson BO, Jensen SM, Suhr OB. Liver transplantation does not prevent the development of life-threatening arrhythmia in familial amyloidotic polyneuropathy, Portuguese-type (ATTR Val30Met) patients. Transplantation 2004; 1: 112-6.

  63. Hornsten R, Pennlert J, Wiklund U, Lindqvist P, Jensen SM, Suhr OB. Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 2010; 2: 63-8.

  64. Stangou AJ, Hawkins PN, Heaton ND, Rela M, Monaghan M, Nihoyannopoulos P, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation 1998; 2: 229-33.

  65. Okamoto S, Hornsten R, Obayashi K, Wijayatunga P, Suhr OB. Continuous development of arrhythmia is observed in Swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant). Liver Transpl 2011; 2: 122-8.

  66. Olofsson BO, Backman C, Karp K, Suhr OB. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002; 5: 745-51.

  67. Sakashita N, Ando Y, Haraoka K, Terazaki H, Yamashita T, Nakamura M, et al. Severe congestive heart failure with cardiac liver cirrhosis 10 years after orthotopic liver transplantation for familial amyloidotic polyneuropathy. Pathol Int 2006; 7: 408-12.

  68. Morelli S, Carmenini E, Sgreccia A, Francia A. Heart rate variability and familial amyloidosis. Int J Cardiol 2002; 3: 295-7.

  69. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006; 17: 1805-13.

  70. Grazi GL, Cescon M, Salvi F, Ercolani G, Ravaioli M, Arpesella G, et al. Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view. Liver Transpl 2003; 9: 986-92.

  71. Barreiros AP, Post F, Hoppe-Lotichius M, Linke RP, Vahl CF, Schafers HJ, et al. Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl 2010; 3: 314-23.

  72. McAlister FA, Bertsch K, Man J, Bradley J, Jacka M. Incidence of and risk factors for pulmonary complications after nonthoracic surgery. Am J Respir Crit Care Med 2005; 5: 514-7.

  73. Rybak D, Fallon MB, Krowka MJ, Brown RS Jr, Reinen J, Stadheim L, et al. Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. Liver Transpl 2008; 9: 1357-65.

  74. Ehlers SL, Rodrigue JR, Widows MR, Reed AI, Nelson DR. Tobacco use before and after liver transplantation: a single center survey and implications for clinical practice and research. Liver Transpl 2004; 3: 412-7.

  75. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 9063: 1436-42.

  76. van der Heide F, Dijkstra G, Porte RJ, Kleibeuker JH, Haagsma EB. Smoking behavior in liver transplant recipients. Liver Transpl 2009; 6: 648-55.

  77. Pauwels RA, Buist AS, Ma P, Jenkins CR, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. Respir Care 2001; 8: 798-825.

  78. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 10: 1005-12.

  79. Alberts WM, Salem AJ, Solomon DA, Boyce G. Hepatic hydrothorax. Cause and management. Arch Intern Med 1991; 12: 2383-8.

  80. Morrow CS, Kantor M, Armen RN. Hepatic hydrothorax. Ann Intern Med 1958; 1: 193-203.

  81. Cardenas A, Kelleher T, Chopra S. Review article: hepatic hydrothorax. Aliment Pharmacol Ther 2004; 3: 271-9.

  82. Serste T, Moreno C, Francoz C, Razek WA, Paugham C, Belghitti J, et al. The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation. Eur J Gastroenterol Hepatol 2010; 2: 207-12.

  83. Xiol X, Tremosa G, Castellote J, Gornals J, Lama C, Lopez C, et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int 2005; 6: 672-5.

  84. Rodriguez-Roisin R, Agusti AG, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 1992; 11: 897-902.

  85. Martinez GP, Barbera JA, Visa J, Rimola A, Pare JC, Roca J, et al. Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol 2001; 5: 651-7.

  86. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996; 1: 17-33.

  87. Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 1996; 1: 1-15.

  88. Rodriguez-Roisin R, Krowka MJ, Herve P, Fallon MB. ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 5: 861-80.

  89. Martinez G, Barbera JA, Navasa M, Roca J, Visa J, Rodriguez- Roisin R. Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol 1999; 5: 882-9.

  90. Abrams GA, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995; 4: 1283-8.

  91. Poterucha JJ, Krowka MJ, Dickson ER, Cortese DA, Stanson AW, Krom RA. Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology 1995; 1: 96-100.

  92. Krowka MJ. Hepatopulmonary syndrome: recent literature (1997 to 1999) and implications for liver transplantation. Liver Transpl 2000; 4(Suppl. 1): S31-S35.

  93. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 5: 1122-9.

  94. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003; 1: 192-7.

  95. Krowka MJ, Wiseman GA, Burnett OL, Spivey JR, Therneau T, Porayko MK, et al. Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)Tc MAA lung scanning. Chest 2000; 3: 615-24.

  96. Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008; 4: 1168-75.

  97. Castro M, Krowka MJ, Schroeder DR, Beck KC, Plevak DJ, Rettke SR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 1996; 6: 543-51.

  98. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000; 4: 443-50.

  99. Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 2: 520-8.

  100. Taura P, Garcia-Valdecasas JC, Beltran J, Izquierdo E, Navasa M, Sala-Blanch J, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesth Analg 1996; 4: 675-80.

  101. Kuo PC, Plotkin JS, Johnson LB, Howell CD, Laurin JM, Bartlett ST, et al. Distinctive clinical features of portopulmonary hypertension. Chest 1997; 4: 980-6.

  102. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000; 4: 453-8.

  103. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology 2006; 6: 1502-10.

  104. Kuo PC, Plotkin JS, Gaine S, Schroeder RA, Rustgi VK, Rubin LJ, et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999; 8: 1087-93.

  105. Reichenberger F, Voswinckel R, Steveling E, Enke B, Kreckel A, Olschewski H, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 3: 563-7.

  106. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 11: 2445-53.

  107. Ricci GL, Melgosa MT, Burgos F, Valera JL, Pizarro S, Roca J, et al. Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension. Liver Transpl 2007; 11: 1506-14.

  108. Ridgway ZA, Howell SJ. Cardiopulmonary exercise testing: a review of methods and applications in surgical patients. Eur J Anaesthesiol 2010; 10: 858-65.

  109. Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl 2010; 12: 1373-8.

  110. Dharancy S, Lemyze M, Boleslawski E, Neviere R, Declerck N, Canva V, et al. Impact of impaired aerobic capacity on liver transplant candidates. Transplantation 2008; 8: 1077-83.




2020     |     www.medigraphic.com